{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:53:15Z","timestamp":1795063995366,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272753"],"award-info":[{"award-number":["82272753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2021LZL002"],"award-info":[{"award-number":["ZR2021LZL002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bethune Cancer Radiotherapy Translational Medicine Research Fund","award":["flzh202103"],"award-info":[{"award-number":["flzh202103"]}]},{"name":"The Key Research and Development Program of Shandong","award":["2021SFGC05012021"],"award-info":[{"award-number":["2021SFGC05012021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14944-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:48:01Z","timestamp":1760456881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study protocol for a single-arm phase Ib\/II trial of Ivonescimab combined with adapted guided stereotactic body radiotherapy and chemotherapy in patients with locally advanced pancreatic cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Ziniu","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"14944_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, Siebenh\u00fcner AR, Winder T, Meisel A, Fritsch R, Astaras C, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"14944_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1827","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang J, Gai J, Zhang T, Niu N, Qi H, Thomas DL 2nd, et al. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Sci Adv. 2024;10(6):eadk1827.","journal-title":"Sci Adv"},{"key":"14944_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594212","volume":"11","author":"P Zhou","year":"2020","unstructured":"Zhou P, Chen D, Zhu B, Chen W, Xie Q, Wang Y, et al. Stereotactic body radiotherapy is effective in modifying the tumor genome and tumor immune microenvironment in non-small cell lung cancer or lung metastatic carcinoma. Front Immunol. 2020;11:594212.","journal-title":"Front Immunol"},{"key":"14944_CR4","doi-asserted-by":"publisher","unstructured":"Ye J, Mills BN, Qin SS, Garrett-Larsen J, Murphy JD, Uccello TP, et al. Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004784.","DOI":"10.1136\/jitc-2022-004784"},{"issue":"7","key":"14944_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.5306\/wjco.v15.i7.859","volume":"15","author":"SQ Zhou","year":"2024","unstructured":"Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol. 2024;15(7):859\u201366.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"14944_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-023-01422-8","volume":"16","author":"S Chen","year":"2023","unstructured":"Chen S, Li J, Dong A, Liu Z, Zhu M, Jin M, et al. Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study. J Hematol Oncol. 2023;16(1):26.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"14944_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100972","volume":"4","author":"J Du","year":"2023","unstructured":"Du J, Lu C, Mao L, Zhu Y, Kong W, Shen S, et al. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: a biomolecular exploratory, phase II trial. Cell Rep Med. 2023;4(3):100972.","journal-title":"Cell Rep Med"},{"key":"14944_CR8","doi-asserted-by":"crossref","unstructured":"Lee V, Ding D, Rodriguez C, Onners B, Zheng LJJoCO: A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).\u00a0J Clin Oncol. 2021;39(15_suppl):4134\u201334.","DOI":"10.1200\/JCO.2021.39.15_suppl.4134"},{"issue":"9","key":"14944_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"1","key":"14944_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","volume":"9","author":"K Cheng","year":"2024","unstructured":"Cheng K, Li X, Lv W, Zhao G, Zhou R, Chang C, et al. Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial. Signal Transduct Target Ther. 2024;9(1):321.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"14944_CR11","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","volume":"26","author":"ZA Wainberg","year":"2020","unstructured":"Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, et al. Open-label, phase I study of Nivolumab combined with nab-Paclitaxel plus Gemcitabine in advanced pancreatic cancer. Clin Cancer Res. 2020;26(18):4814\u201322.","journal-title":"Clin Cancer Res"},{"key":"14944_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009722","author":"FA Sinicrope","year":"2024","unstructured":"Sinicrope FA, Turk MJ. Immune checkpoint blockade: timing is everything. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009722.","journal-title":"J Immunother Cancer"},{"key":"14944_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2024.08.006","volume":"174","author":"ZY Jia","year":"2024","unstructured":"Jia ZY, Yan X, Zhou H, Wang W, Li C, Zhang BL. Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer. Mol Immunol. 2024;174:69\u201376.","journal-title":"Mol Immunol"},{"key":"14944_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med"},{"key":"14944_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2023.102058","author":"L Luo","year":"2024","unstructured":"Luo L, Wang X, Liao YP, Xu X, Chang CH, Nel AE. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano Today. 2024. https:\/\/doi.org\/10.1016\/j.nantod.2023.102058.","journal-title":"Nano Today"},{"key":"14944_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877","volume":"11","author":"SP Hack","year":"2020","unstructured":"Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877.","journal-title":"Front Immunol"},{"issue":"4","key":"14944_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035\u201343.","journal-title":"Nat Med"},{"key":"14944_CR18","doi-asserted-by":"crossref","unstructured":"Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Ya\u00f1ez E, G\u00fcm\u00fc\u015f M, de Hurtado Mendoza MO, et al.\u00a0Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol\u00a02023 24(4):392\u2013402.","DOI":"10.1016\/S1470-2045(23)00052-9"},{"issue":"641","key":"14944_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm6420","volume":"14","author":"P Msaouel","year":"2022","unstructured":"Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, et al. A phase 1\u20132 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022;14(641):eabm6420.","journal-title":"Sci Transl Med"},{"issue":"9","key":"14944_CR20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Ivonescimab: first approval. Drugs. 2024;84(9):1135\u201342.","journal-title":"Drugs"},{"issue":"7","key":"14944_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","volume":"54","author":"EA Mellon","year":"2015","unstructured":"Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta oncologica (Stockholm, Sweden). 2015;54(7):979\u201385.","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"key":"14944_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110347","volume":"197","author":"M Weisz Ejlsmark","year":"2024","unstructured":"Weisz Ejlsmark M, Bahij R, Schytte T, R\u00f8nn Hansen C, Bertelsen A, Mahmood F, et al. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - a phase II study. Radiother Oncol. 2024;197:110347.","journal-title":"Radiother Oncol"},{"issue":"22","key":"14944_CR23","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1001\/jama.2022.21022","volume":"328","author":"NJ Butcher","year":"2022","unstructured":"Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, et al. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022;328(22):2252\u201364.","journal-title":"JAMA"},{"issue":"1","key":"14944_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12885-020-07764-7","volume":"21","author":"X Wang","year":"2021","unstructured":"Wang X, Li S, Sun Y, Li K, Shen X, Xue Y, et al. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer. 2021;21(1):20.","journal-title":"BMC Cancer"},{"key":"14944_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62:102106.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"14944_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60.","journal-title":"Mol Cancer"},{"issue":"7","key":"14944_CR27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/annonc\/mdx174","volume":"28","author":"J Taieb","year":"2017","unstructured":"Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, et al. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28(7):1473\u201383.","journal-title":"Ann Oncol"},{"key":"14944_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","author":"S Frentzas","year":"2024","unstructured":"Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, Underhill C, Wang W, et al. Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008037.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"14944_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2487512","volume":"25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu X, Ren S. Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis. Expert Opin Biol Ther. 2025;25(5):1\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"14944_CR30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S1470-2045(23)00478-3","volume":"24","author":"CM Taniguchi","year":"2023","unstructured":"Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, et al. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b\/2 trial. Lancet Oncol. 2023;24(12):1387\u201398.","journal-title":"Lancet Oncol"},{"issue":"7","key":"14944_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370.","journal-title":"JAMA"},{"key":"14944_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2019.01.020","volume":"134","author":"M Loi","year":"2019","unstructured":"Loi M, Magallon-Baro A, Suker M, van Eijck C, Sharma A, Hoogeman M, et al. Pancreatic cancer treated with SBRT: effect of anatomical interfraction variations on dose to organs at risk. Radiother Oncol. 2019;134:67\u201373.","journal-title":"Radiother Oncol"},{"key":"14944_CR33","doi-asserted-by":"crossref","unstructured":"Chen Z, Wu L, Wang Q, Yu Y, Liu X, Ma R, Li T, Li Y, Song X, Li L et al: Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial. J Thor Oncol: Off Publ Intern Assoc Study Lung Cancer 2025;20:233\u20139.","DOI":"10.1016\/j.jtho.2024.10.013"},{"issue":"7797","key":"14944_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","volume":"579","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579(7797):130\u20135.","journal-title":"Nature"},{"issue":"3","key":"14944_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071\u2013121.","journal-title":"Physiol Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14944-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:09:11Z","timestamp":1760494151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14944-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14944"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14944-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University approved the final protocol (Approval No. SDZLEC2024-414\u201302) in accordance with the Declaration of Helsinki and Good Clinical Practice principles. All patients will provide written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1581"}}